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~Jbjertives. ‘I% study examined the effects of cmt~urrent 
diuretic therapy on the hemcdynamic responres to short.term and 
sustained therapy with tranrdermal nilroglyceris. 
Background. Sodium relentinn and plasma volume axpnnsion 
nccur during therapy with nitroglycerin and may play a role in the 
lw of nttrogtycertn e&cb during sustained therapy. 
Me,,,,,& Taenty.,wo normPl male ralunteers were treated for 
1 week with either hydrwhlorothitide and amiloride (50 + 5 mg, 
(n = 1,) or placebo (n = II) in a randomized, double-blind 
fashion. All 22 subjects then received continunus IranSdermal 
nitmglyeerin 09 I 1 m/?d hJ for 5 to 7 days. 
I&w&. On the hrst and tert day oftransdermnt nitroglycerin 
therapy, standing heart rate, systolic blood pressure and hemato- 
wit values were assessed at g. 9 and 10 AM and 12 noon. Heart rate 
and hlwd pressure responses to sublingual nitroglycerin (0.6 mg) 
Organic nitrates arc commonly used in the therapy of angina 
pcctoris and congestive heart failure. It is now recognized 
that these agents lose their effectiveness during sustained 
therapy, and several investigations (I-10) have dcmon- 
stratcd rapid attenuation of both the hemodynamic and the 
antianginal effects of oral. topical and intravenously admin- 
istered nitrates. The basis of nitrate tolerance is not com- 
pletely understood. Most investigations (1 I) have focused on 
the mechanisms underlying nitrate-mediated vascular Lila- 
lion and the theory that nilrate tolerance occurs because of 
depletion of reduced sullhydryl groups in the vascular 
smooth muscle. Recently, there has been increasing cvi- 
dcnce (12-15) that reflex neurohormonal responses, which 
induce plasma volume expansion and augment vasoconatric- 
tar forces, may play an important role in the attenuation of 
nitrate responsiveoees. Purthcrmore. therapy with diuretic 
were also evaluated belore and atIer sustained transderma, niho- 
glycerin therapy. A si#dPrant IDIS al the hemodynamic e&cb 0, 
transderlnal and snhllngual rdtrogly&n occurred daring sus- 
taincd therapy in bath the diuretic and placebutherapy groups. In 
both groups, tranrdermal nilrnglycrrin thwapy wps associated 
with a rienidcant deereasp in bentatncrit that wrristed for the 
entire treatment ported. 
Conclusions. These results suggest that diuretic therapy dces 
not prevent plasma volume expansion or the loss of henwdynandc 
etlerts during sustained transdermal nitroglycerin therapy. The 
persistent decrease in hematocrlt suggests that plasma volume 
expandon plays a role in the attenuation of nitrate eUects. II also 
provides ovldence ol continued vascular acttvity of nitroglycerin 
despite loss of syttanic bemodynamic efkts. 
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agents and with angiotensin-converting enzyme inhibitors 
has been shown (16.17) to prevent loss of the effects of the 
organic nitrates during sustained therapy. 
In this studv. we evaluated the effects of concurrent 
diuretic therapy on hemodynamic responses to continuous 
transdcmtal nitroglycerin in a group of normal subjects. WC 
hypothesized that the use of a diuretic agent would prevent 
sodium retention, modify plasma volume expansion and thus 
partially prevent the rapid loss of hemodynamic responses 
typically associated with sustained nitroglycerin therapy. 
Methods 
Study subjects. The study group consisted of 22 nom%4 
riaic volunteers aged 20 to 31 years with no history of renal 
or cardiac disease. The results of physical examination, 
urinalysis and determination of blood urea nitrogen. creati- 
nine, &ctrolytes and hematocrit were normal in aI1 subjects. 
No subject was taking medications at the time of the 
investigation. 
The study protocol was approved by the Ethics Commit- 
tee of Queen’s University, Kingston, Ontario, Canada, and 
written informed consent was obtained from all volunteers. 
Visit I. During this initial visit, subjects were seen as 
outpatients and they underwent a screening medical history 
and physical examinalion and nitroglycerin dose titration. 
Each subject initially received a patch delivering nitroglyc- 
win at a rate of IO mgi24 h (Transderm Nitro. Ciba-Geigy 
Canada :nc.). and blood pressure uak recorded. with rhe 
subject standing, every it! min for the next 2 h. The xm 
was to achieve a decrease in systolic biood prerwrc uf lo 
to 20 mm Hg without gcing below 90 mm Hg. If an adequate 
blood pressure resporw! was not achieved after 2 h with the 
single nitroglycerin patch, a second IO-mg patch was sp- 
plied. The maximal dose used v&s 20 mgl14 h: if the dewed 
hypotensive effect v~as not observed. the subject wns not 
entered into the study. When titration was complctc. ,ub- 
jects were randomized to therapy with either the diuretic 
agent Moduretic (hydrochlorothiazide. 50 mg, plus amilo- 
ride, 5 mg) or the matching placebo in a double-blind. 
randomized fashion. They were instructed to take the study 
medication daily at 8~30 AM. 
Visit 2. Aiier 7 days, subjects returned to the cardiovrs- 
cular laboratory at 7:30 AM. At 8 AM the standing heart vate 
and bkwd pressure were determmed and the oral study medi- 
cation was administered. Blood pressure was measured by 
trained personnel using a sphygmomanometer. Three separate 
measurements were made at I-min intervals and the results 
averaged. Heart rate was determined froma I-min pulse count. 
Subsequently, standing heart rate and blood oressum were 
mea&d at-9 AM, 10-w and 12 no+“. After -measurements 
were taken ai I2 noa, 0.6 mg of sublingual nitroglycerin was 
administered and the subject was instructed to remain stmd- 
ing. Heart rate and blood pressure were recorded 3.6 and 9 mm 
after the administration of nitroglycerin. 
Visit 3. The followiw dav. subiects returned to the cardip _ 
vascular b.bmatmy at 7: I5 A.M. vie” an l&gauge heparin lock 
was established in the nondominant forearm to allow venous 
blood sampling. After 30 min of quiet rest, standing heart rate 
and blood pressure were determined and a venous blood 
sample for hematocrit detemkation was drawn at 8 AM. When 
these measwerrrcnts had been completed, a nitroglycerin patch 
was applied to a hairless area of the torso and subjects were 
@ven their oral study medication. Subseqzcnt hemcdynamic 
measurements and blood samples vere taken at 9 AM. IO AM 
and 12 ttcan. The heparin lock was then removed and the 
suhiect wasgiven a SUDRIY oftransdermal nitroglycerin patches 
to be applia once daily and IeR in place for %h. 
W&i 4. A&r 5 to 7 davs. subiects returned to the cardio- 
va.scular laboratory at 7: lj ;M a;ld venous access WBS again 
established as previously described. After 30 min of quiet rest, 
measurements similar to those obtained at visit 3 were per- 
formed at 8 AM. At that point the nitroglycerin patch was 
changed. the oml study medication wan administered and 
repeat mca.surements were made at 9 AM. IO AM and I2 noon. 
After the I2 noon measttrcmentr. 0.6 mg of sublingual nitro- 
&win was administered and the subject was instructed to 
rcmti standing. Ilsml rate and bloat pxssurc were recorded 
3.6 and 9 min&er the administration of nitroglycerin. 
Statistical metlmds. All data are presented as mean value 
r SEM. Data were analyzed by means of a repeated 
measures analysis of variattce. with days, hours or minutes 
as within-subjects &cts and treatment group (diuretic agent 
vs. placebo1 as a between-subject effect. This dcsrgn yielded 
re\!\ of I, whether mean values of theic meawrcmentc 
vancd rigniBcantly among daya: 2) whether they exhibwd a 
pmtern oi variation resulting in significant differences acru~, 
hour? or minutes: 31 whether the daily effect varied as d 
functmn o!’ the time at which valw wcrc measured: and 
11 whether the daily. hour or minute etfccts vancd ab a 
function of trcatmcnt with diuretic agent versus placebo. In 
care> uherc significant F values were found. specific pre- 
planned comparisons between baseline and subsequent daba 
points were performed. For heart rate and blood pressure 
responses to transdermal nitroglycerin. visi! 2 served ar 
taseline for the day effecr, and 8 AH served as baseline for 
rhe hourly etTect. For hematocril vahw, visi: 3 rerved as 
basebne for the day etfcct and 8 AM as haselinc ior the hourly 
e&t. Finally. for responses to sublingual nitroglycerin, 
visit 2 served as baseline for the day effect and time 0 as 
baseline fw the minute &CL Differences were considered 
significant if the null hypothesis could be rejeaed at the 0.05 
probability level. 
Results 
Diwe’ic sod tmnsdermal nit*yeerin therapy. A totai of 
22 patients vcre randomized, I I received Mod&&c and rhe 
remainder received olacebo. The nirrodyceiin dose used 
was that determined from ihc dose t&ion carried out 
during the out-of-hospital phase. The mean nitmglycerio 
dose in both groups was 19 5 I mgl24 h. 
Baseline blood prewre and hcprt rate (Fig. I and 2). 
Sisnding systolic blood pressure on visit 2 (the day of imtial 
sublingual nitroglycerin administration) was similar in the 
diuretic and placebo therapy groups. Basel?~e heart rate at 
8 AM was higher in the diuretic therapy group although there 
was no difference in heart rate between the treatment groups 
81 other times of day. 
Heart rate md l!&wd pIcvure respwwr to trarisdermnl 
nitroglycerin (Fig. I and 2). In both the diuretic and placebo 
therapy groups, the initial application of trmndermal nitm- 
8!jcei;n iGil 3j was ansoctated with a significant decrease in 
systolic blood pressure that persisted for the 4-h observation 
period. This decrease was accompanied by a significant 
increrw in heart rate that also was seen thmughout the 
observation period. Analysis of variance showed no diffcr- 
ewes in the response of the two therapy groups. At 8 AM on 
visit 4. after 5 to 7 days of continuous nitroglycerin therapy, 
systolic blood pressure and heart rate in both groups had 
returned to baseline valttes and were not significantly diier- 
cnt from those observed on visit 2. Aftcr patch application 
on wsit 4. no significant change in systolic blood pressure 
was observed in the placebo therapy group. In the group 
taking a diuretic agent. there was a modest decrease (p = 
NS) in standing systolic blood pressure after repeat patch 
application. After patch reapplication on visit 4, both groups 
had a significant increase in heart rate that persisted for tne 4-h 
F&m 2 (b&w). Standing bcti me (beatsimin [BPMI) at baseline, 
afler short-Ien therapy wtb tmnsdermal nilmglycedn (GTN) on 
visit 3 and after sustained transdermti rdtmgiycerin therapy on visit 
4. Panrl A, Placebo therapy group. Panel B. Diuretic tbcrapy group. 
Values are mean v& f SEM. *p < 0.05, main effect of hours in 
an&y% of variance; tp -C 0.05, hours by day interaction in analysis 
of variance; both from preplanned comparisom bewee” 8 AM and 
each subsequent time point. Hours as in Figure 1. 
A. 
observation period, but this increase was now signilicanlly less 
than Ihal seen a&r initial patch application on visit 3. 
Heart rate and blwd pre%ure ‘espofises to sublinyel 
nilrwlvcrrin (Fie. 3 and 4). In both the placebc and diuretic 
tber& groups,.the acute administratidn of 0.6 mg of rub- 
lingual nitroglycerin on visi’ 2 (while subjects were in the 
nitrate-free stale) was associated with a signifuxnt decrease 
in standing systolic blood pressure, accompanied by a sig- 
nificant increase in heart rate. These changes persisted 
throughout the 9.min observation period. The observed 
hemodynamic responses to sublingual nitroglycetin were 
similar in the two groups. Mer 5 to 7 days of sustained 
tmnsdemml nitroglycerin therapy, the administration of sub- 
lingual nitroglycerin continued to be associated with a sig- 
nificant decrease in systolic blood Pressure and a significant 
increase in heart rate, although these responses were signif- 
8. 
Tii (hrs) - IbJ 
icantly less than those seen during the administration of 
sublingual nitmglycetin in the nitrate-free state. Once again. 
analysis of variance showed that these responses did not 
vary as a function of treatmeoi group. 
Aematocril rewmsw to trandemtal nilrwtvcerin tFie. 5). 
Baseliz hem&it at 8 AM on visit 3 was s,&u in ;h;two 
~IOUDS. On visit 4, after 5 to 7 days of sustained c’ aeivcerin 
~~?I&. hematwrit values in boil, groups wrr aignkndy 
laker than they were at baseline throughout the entire 4-h 
observation period. There was no significant difference in 
the pattern of hematocrit change after short-term and sw- 
tained tmnsdermal nitroglycerin therapy in the $xcbo and 
diuretic therapy groups. 
Discussion 
Mechanism ofttitrate tolerance. Althoqh there continues 
to be evidence that nitrate tolerance is in part due to a loss of 
*. 
.i at 3.6 and 9 mi” aft& short-term rubbnrmat &o&en” IS,. 
GTNI in the nitrate-free slate on visit Z.-and after sublineual 
nitmglycerin administration during swawd transdermal nitro& 
win tTD GTNI therapy on visb 4. f’anct A. Placebo therapy group. 
Panel g. Diuetic therapy group. Valuer are mean value i SEM. 
*p C W. main effect of minutes in analysis of variance. ip < 0.05. 
minutes by day interaction in analysis of variance; borh from 
;;q;,l:med compari~ana between time 0 and ~~bseeqwm dime 
0. 
Q-! _.-__ ..-... , _ 
. 3 ‘ , e 3 ‘ , 
DIinvlaP~rrsL GTN 
Time (hrs) 
Figure 5. Hcmatoed values in IilWS per liter (LIL) aher shon-term 
theraov with transdermal nitmelvcerin (GTN) an visit 3 and after 
pat& kappbcatian during sust&ed tratkdermal nitroglycerin ther- 
apy en visit 4. Panel A, Placebo therapy group. Panel B. Diuretk 
therapy gmup. Values are mean value t SEM. *p < o.05. hours by 
day interaction i analysis of variance. Houra as in Figure 1. 
the direct pharmacologic vasodilating properties of these 
agents secondary to sullhydryl group depletion at the level of 
vascular smooth muscle, this issue remains controversial 
(18-23). There is now increasing evidence that reflex, coun- 
terregulatory responses may be pxtially responsible for the 
loss of effective&s cccur&g d&g s&d&d therapy with 
organic nitrates. In nomml volunteers (12.13) and in patients 
with heart failure (10,14,24,25), a number of studies have 
now demonstrated that nitrate therapy is associated with a 
variety of ncurohormonal responses that are accompanied 
by evidence of plasma volume expansion. Many of the 
hemodynamic and symptomatic responses lo nitrate therapy 
result from the potent preload-reducing cUeects of these 
agents(26). We (13)andothers (10,14,15) have hypothesized 
that the release of endogenous vasoconstrictors, retention of 
sodium and expansion of plasma volume would tend to 
reverse the preload reduction caused by nitrtttes, restore 
intracardiac pressures toward normal, thus diminishing their 
clinical effectiveness. These responses cac!d blunt effec- 
tively the hemodynamic responses to nitrates even though 
the drugs remained active at the vascular level. 
Counterregulatory restwnses and the prevention of nitrale 
tolerance. These findings have led to &empts to prevent 
nittdte tolerance through the use of oharmacolozic interven- 
tions designed to inhtbit or circumvktt these c&nterregula- 
tory responses. In a recent investigation, Katz et al. (17) 
demonstrated that angiotcnsin-converting enzyme inhibitors 
were useful in preventing the loss of effectiveness of trans- 
derttml nitroglycerin as assessed by forearm venws re- 
spmtscs. Further, in patients with angina, a preliminary 
report (27) found that angiotensin-converting enzyme inhibi- 
tion ws effective in maintaining improvement in treadmill 
walking time during sustained therapy with transdemxd 
nitroglycerin. 
It has also been suggested (16) that concurrent therapy 
with diuretic acents mieht be useful in the txevention of 
nitrate tolerant;. Evidence of plasma volume &pansion has 
been a consistent finding in several studies (12-14) address- 
ing the counterregulatory responses to the organic nitrates. 
It is possible that diuretic therapy would prevent such 
volume expansion, thus maintaining the preload reduction 
that OCCUFS during short-term administration of organic 
nitrates. The present study suggests that diuretic therapy 
does not prevent loss of the hemodynamic effects of sus- 
tained therapy with transdetmal nitroglycerin. Despite can- 
current therapy with a diuretic agent. hemodvnamic re. 
sponses to r&at patch application were not significantly 
different from those observed at baseline or after sustained 
transdemtal nitroglycerin therapy in the placebo group. 
Furthermore, concurrent diuretic therapy did not appear to 
modify the bemodynamic response to sublingual nitroglyc- 
erin either in the nitrate-free slate or after sustained therapy 
with transdertttal nitroglycerin. 
Previous studies. The findings of the present study are in 
disagreement with the preliminary report of Sussex et al. 
(16). Their investigation suggested that therapy with 
Moderelic was able to prevent the development of tolerance 
to isosorbide dinitrate. given 4 times daily, in a group of 
patients with angina. Unfortunately their trial did not assess 
the impact of the diuretic agent alone on exercise petfor- 
mance. Because diuretic therapy might have independent 
effects on exercise performance in angina (261, it is not 
possible to conclude definitively fmm their investigation that 
nitrate tolerance can be prevented through the use ofdiuretic 
agents. It should be emphasized that the disparate results of 
the two investigations may be explained by 1) differences in 
the degree of tolerance induced during oral dosing of iso- 
sorbide dinitrate as compared with continuous transdermal 
nitroglycerin: 2) the inclusion in our investigation at normal 
volunteers rather than patients with coronary tiery disease; 
and 3) the possibility that the results of the investi@ion of 
Sussex et al. 116) may reflect a pern~stent effect of the 
combination of diuretic agents and isosorbidc dinitrate on 
ventricular @“ad that was not detected by measurement of 
systemic arterial blood pressure and heart rate. 
hcmr+!& reen during &stained transdermal nitroglycerin 
therapy. The observed decrease in hematocrit reflects the 
plasma volume expansion that has been shown to occur 
Strengths and limitations of the present study. Thcrc are 
several possible explanations for the inability of concurrent 
during therapy with organic nitrates tt2-IQ). The inability of 
diuretic therapy to prevent the attenuation of nitrate effects 
during sustained therapy. First, although the dose of thmzide 
diuretic agent used in this study war the same as that used in 
the investigation of Sussex et al. (16) and has been shown to 
eause a significant narriuresis in humans (29;. it is passable 
that a larger dose or the use of a more potent diuretic agent 
would have produced a different result. Further. the use of a 
diuretic agent did not atwar to modify the decrease in 
Second. the hemodynamic respoase to sublingual nitrw 
dycerin remained significant even though it ws slightly 
attenuated after 5 to 7 days of continuous tnnsdermal 
nitroglycerin therapy. This finding confirms obnervatioos 
t?.Ztt in subjects made tolerant to administrafion of iscsor- 
bide dinitrate 4 times daily. 31) whom sublingual nitroglycerin 
was associated with continued significant hemodynamic and 
antianginal responses. Finally. although there was etear 
attenuation of the transderma! niirogiycerin effect on heart 
rate DYCT tvne. heart rete continued to increase significantly 
after patch reapplication after the 5 to 7 day period of 
sustained therapy. 
that &str for at least 5 to 7 d&s of continuous therap;. 
This view IS consistent with the sulfhydryl group depletion 
hypotheses, as the significant attenuation of the response to 
sublingual nitroglycerin could be explained by a shift in the 
We believe that. teken together, these observations 
srronglv wggest thsg continuous therapy wirh transdermzal 
nitroslycerin is asswiated with sianiticant vascular activitv 
diuretic therapy to prevent plasma volume expansion during dose-response curve secondary to &lhydryl group deple- 
sustained transdermal nitroglycerin therapy may reflect the lion. Nevertheless. these responses are also consistent with 
fact that plasma volume expands not only because of renal the hypothesis that countenzgulatory responses and plasma 
sodium retention hut also because of a relocation of ex- volume expansion lead to the reversal of the hemodynamic 
travascular fluid to the intravascular space. The latter phe- and clinical ei%cacy of continuously administered nitroglyc- 
nomenon is believed to be II result of the potent effects of ertn even when the compound remains active at the vascular 
nitroglycerin on venule~ that alter Starling forces in a man- smootn muscle cell level. 
ner that favors expansion ofplasma volume (14). If this is the ConeMom. This investigation suggests that diuretic 
case, it is quite possible that diuretic therapy alone would therapy does not prevent the plasma volume expansion seen 
not be a successIiil aauroach to ureventinz volume exoan- during continuous therapy with nitroglycerin. The results 
tory responses &at include the release of catecholar&es 
sion. 
and activation of the reninangiotensin system (30.31). That 
heart rate tended to be higher at 8 AM on visits 2. 3 and 4 in 
the diuretic therapy group may well be a reflection of such 
Diuretic theraw itself is associated with counterre~ula- 
responses. It is possible that any beneficial effects ofdiuretic 
ag.&s on sodi& retention were counterbalanced by such 
responses. Finally, it is possible that the results of our study 
represent a type II statistical error and that the investigation 
of a larger number of subjects would have yielded a positive 
resLdt. 
Evidence of continued va.wo&ar aetitity of nitroglycerin. 
Despite :he lack of a hemodynamic response to repeated 
patch app!icrdion after 5 to 7 days of continuous transdermal 
nitroglycerin therapy, there was evidence that the organic 
nitwe was exerting a vascular effect. First, despite the loss 
of hemodynamic e&et of transdennal nitroglycerin after 5 to 
7 days of continuous therapy, persistent plasma volume 
expansion was manifested by a continued decrease in hem- 
at&t. Although plasma volume was not directly measured 
in this study, changes in hematocrit aRer nitroglycerin 
therapy have been shown to closely parallel changes in 
measured plasma volume (14). That hematocrit values re- 
mained significantly lower than control values tier 5 to 7 
days of continuous transdermal nitroglycerin therapy sug- 
gests that the drug continued to have significant effects. 
p~marily by a fluid shift from the extravarc&fluid com- 
panment 10 the intravascular space. These di?ta also suggest 
provide support for the hypothesis that plasma volume 
that loss of!he hemodynamic effects ofcontinuous nitroglyc- 
erin therapy during sustained therapy does not necessarily 
expansion associated with ownic nitrate theraw is caused 
reflect tctal loss of effect of these agents at the vascular 
level. They emphasize that plasma volume expansion may 
play an important mle inths loss ofnitrateeffects overtime. 
Further mveatigation will be needed to determine whether 
nitrate-induced plasma volume expansion can b-e prevented 
and. if so, whether this would be associated with sustained 
hemodynamic and clinical effectiveness during continuous 
therapy with the organic nitrates. 
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